Compare · ANVS vs JNJ
ANVS vs JNJ
Side-by-side comparison of Annovis Bio Inc. (ANVS) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANVS and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $547.28B, about 4935.0x ANVS ($110.9M).
- Over the past year, ANVS is up 23.8% and JNJ is up 45.5% - JNJ leads by 21.6 points.
- JNJ has been more active in the news (28 items in the past 4 weeks vs 5 for ANVS).
- JNJ has more recent analyst coverage (25 ratings vs 4 for ANVS).
- Company
- Annovis Bio Inc.
- Johnson & Johnson
- Price
- $1.84-1.34%
- $227.31-0.19%
- Market cap
- $110.9M
- $547.28B
- 1M return
- -7.29%
- -6.26%
- 1Y return
- +23.83%
- +45.46%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2020
- News (4w)
- 5
- 28
- Recent ratings
- 4
- 25
Annovis Bio Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ANVS
- Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
- Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
- SEC Form 424B5 filed by Annovis Bio Inc.
- Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
- The Credibility Filter Wall Street Uses to Sort Biotech Winners
- SEC Form 4 filed by Hoffman Michael B
- Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
- Annovis Publishes Historical Review of Buntanetap in The Scientist
- Annovis Bio Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
Latest JNJ
- Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
- Johnson & Johnson filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Woods Eugene A.
- SEC Form 4 filed by Director West Nadja
- SEC Form 4 filed by Director Weinberger Mark A
- SEC Form 4 filed by Director Pinto Daniel E
- SEC Form 4 filed by Director Morikis John G
- SEC Form 4 filed by Director Mcclellan Mark B.
- SEC Form 4 filed by Director Joly Hubert
- SEC Form 4 filed by Director Johnson Paula A